Hermann Area District Hospital | |
509 W 18th St, Hermann, Missouri 65041 | |
(573) 486-2191 | |
Not Available |
Name | Hermann Area District Hospital |
---|---|
Type | Critical Access Hospital |
Location | 509 W 18th St, Hermann, Missouri |
Ownership | Government - Hospital District or Authority |
Emergency Services | Yes |
Medicare ID (CCN) | 261314 |
NPI Number | 1962578609 |
Organization Name | HERMANN AREA HOSPITAL DISTRICT |
Doing Business As | HERMANN AREA DISTRICT HOSPITAL |
Address | 509 West 18th St, Hermann, MO 65041 |
Hospital Type | General Acute Care Hospital - Critical Access |
Phone Number | 573-486-2191 |
News Archive
The Health Council of Canada applauds the British Columbia Ministry of Health Services and the B.C. Medical Association on their June 24, 2010 announcement of $137 million toward integrated primary and community care that will connect every resident with a family doctor by 2015, starting with the province's most vulnerable citizens - high needs patients, frail seniors and patients with chronic diseases.
A handheld, ultra-portable device that can recognize and immediately report on a wide variety of environmental or medical compounds may eventually be possible, using a method that incorporates a mixture of biologically tagged nanowires onto integrated circuit chips, according to Penn State researchers.
As an advocate of regular dental care, 1-800-DENTIST® understands that many people can't afford the dentistry they need. That's why the nation's leading free resource for consumers in search of a dentist has launched a nationwide $30,000 smile makeover contest called "My Smile Bites." To enter, contestants must upload a personal video showing what's wrong with their smile, explaining how these problems affect their lives. Video submissions will be accepted through November 10, 2009 noon PST.
Nearly two decades after they identified the specific genetic flaw that causes a common type of muscular dystrophy, scientists believe they have figured out how that flaw brings about the disease. The finding by an international team of researchers settles a longstanding question about the roots of facioscapulohumeral muscular dystrophy or FSHD.
Geron Corporation today announced enrollment of the first patient in a Phase 2 clinical trial to evaluate the activity of the company's telomerase inhibitor drug, imetelstat (GRN163L), in patients with essential thrombocythemia (ET).
› Verified 6 days ago
Able to receive lab results electronically | Not Available |
Able to track patients' lab results, tests, and referrals electronically between visits | Not Available |
News Archive
The Health Council of Canada applauds the British Columbia Ministry of Health Services and the B.C. Medical Association on their June 24, 2010 announcement of $137 million toward integrated primary and community care that will connect every resident with a family doctor by 2015, starting with the province's most vulnerable citizens - high needs patients, frail seniors and patients with chronic diseases.
A handheld, ultra-portable device that can recognize and immediately report on a wide variety of environmental or medical compounds may eventually be possible, using a method that incorporates a mixture of biologically tagged nanowires onto integrated circuit chips, according to Penn State researchers.
As an advocate of regular dental care, 1-800-DENTIST® understands that many people can't afford the dentistry they need. That's why the nation's leading free resource for consumers in search of a dentist has launched a nationwide $30,000 smile makeover contest called "My Smile Bites." To enter, contestants must upload a personal video showing what's wrong with their smile, explaining how these problems affect their lives. Video submissions will be accepted through November 10, 2009 noon PST.
Nearly two decades after they identified the specific genetic flaw that causes a common type of muscular dystrophy, scientists believe they have figured out how that flaw brings about the disease. The finding by an international team of researchers settles a longstanding question about the roots of facioscapulohumeral muscular dystrophy or FSHD.
Geron Corporation today announced enrollment of the first patient in a Phase 2 clinical trial to evaluate the activity of the company's telomerase inhibitor drug, imetelstat (GRN163L), in patients with essential thrombocythemia (ET).
› Verified 6 days ago
Hermann Area District Hospital Critical Access Hospital Location: 509 W 18th St, Hermann, Missouri 65041 Phone: (573) 486-2191 |